A nebulized complex traditional Chinese medicine inhibits Histamine and IL-4 production by ovalbumin in guinea pigs and can stabilize mast cells in vitro

BMC Complementary and Alternative Medicine

Oi-Tong Mak⁴  Chi-Lim Chan²  Cheng-Chung Gong¹  Hung-Chou Chang³ 

[1] Department of Medical Technology, Chung Hwa University of Medicine Technology, Jen-Te, Tainan, Taiwan, ROC;Department of Life Sciences, National Cheng Kung University, Tainan, Taiwan, ROC;Office of Academic Affairs, Tainan Tzu-Chi Senior High School, Tainan, Taiwan, ROC;Department of Healthcare Management, University of Kang Ning, 188, Sec. 5, An Chung Rd. A Nan District, Tainan, Taiwan, ROC

关键词: Ovalbumin;    Chinese medicine;    Drug delivery;    Nebulization;    Asthma;   

Others  :  1221072
DOI  :  10.1186/1472-6882-13-174

 received in 2013-01-26, accepted in 2013-07-01,  发布年份 2013

【 摘 要 】

Background

Traditional Chinese medicines have been used for anti-asthma treatment for several centuries in many Asian countries, and have been shown to effectively relieve symptoms. Our previous study demonstrated that a complex traditional Chinese medicine (CTCM) administered in nebulized form through the intratracheal route is effective against early-phase air-flow obstruction and can inhibit IL-5 production in ovalbumin (OVA)-sensitized guinea pigs. However, the antiasthmatic mechanisms of CTCMs are still unclear.

Methods

In this study, we examined the underlying mechanism of a CTCM that we used in our previous study in order to ascertain its function in the early-phase response to OVA challenge.

In each group, 10–12 unsensitized or OVA-sensitized guinea pigs were treated with nebulized CTCM before OVA challenge, and the airway responses of the animals to OVA were recorded. Bronchoalveolar lavage fluid (BALF) samples were collected 5 min after OVA challenge, and the histamine and IL-4 contents in the BALF were measured. P815 cells (a mouse mast cell line) were untreated or pretreated with CTCM or cromolyn sodium (a mast cell stabilizer), and incubated with Compound 48/80 (mast cell activator) for 9 hr. The levels of histamine and IL-4 released from the cells were quantified.

Results

We found that the inhibition of bronchoconstriction by the CTCM was attenuated by pretreatment with propranolol, suggesting that the CTCM has a bronchodilator effect that is associated with beta-adrenergic receptor. Our results also showed that the CTCM inhibited histamine and IL-4 secretion in the OVA-induced airway hypersensitivity in guinea pigs at 5 min post-OVA challenge, and in vitro study revealed that the CTCM is able to stabilize mast cells.

Conclusion

In conclusion, our results suggested that the CTCM is a kind of bronchodilator and also a mast cell stabilizer. Our findings provide useful information regarding the possible mechanism of the CTCM, and show its potential for application in the treatment of allergenic airway disease.

【 授权许可】

   
2013 Chang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000, 161(5):1720-1745.
• [2]Berend N, Salome CM, King GG: Mechanisms of airway hyperresponsiveness in asthma. Respirology 2008, 13(5):624-631.
• [3]Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ: Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006, 116(6):1633-1641.
• [4]Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B, Collins JV, Durham S, Kay AB: Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990, 142(6 Pt 1):1407-1413.
• [5]Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991, 87(5):893-910.
• [6]Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST: Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis 1990, 142(4):863-871.
• [7]Barnes PJ: New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010, 31(7):335-343.
• [8]Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al.: Eosinophilic inflammation in asthma. N Engl J Med 1990, 323(15):1033-1039.
• [9]Busse WW: The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996, 26(8):868-879.
• [10]Lee T, Lenihan DJ, Malone B, Roddy LL, Wasserman SI: Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem 1984, 259(9):5526-5530.
• [11]Boyce JA: Mast cells: beyond IgE. J Allergy Clin Immunol 2003, 111(1):24-32. quiz 33
• [12]Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M: Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005, 23:749-786.
• [13]Robinson DS: The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 2004, 114(1):58-65.
• [14]Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST: Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994, 10(5):471-480.
• [15]Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britten K, Bews JP, Hunt TC, Okayama Y, Heusser CH, et al.: Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992, 176(5):1381-1386.
• [16]Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, Howarth PH: Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993, 151(7):3853-3865.
• [17]Bradding P, Holgate ST: Immunopathology and human mast cell cytokines. Crit Rev Oncol Hematol 1999, 31(2):119-133.
• [18]Toru H, Pawankar R, Ra C, Yata J, Nakahata T: Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol 1998, 102(3):491-502.
• [19]Romagnani S: Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004, 113(3):395-400.
• [20]Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6(10):761-771.
• [21]Kao ST, Chang CH, Chen YS, Chiang SY, Lin JG: Effects of Ding-Chuan-Tang on bronchoconstriction and airway leucocyte infiltration in sensitized guinea pigs. Immunopharmacol Immunotoxicol 2004, 26(1):113-124.
• [22]Kao ST, Lin CS, Hsieh CC, Hsieh WT, Lin JG: Effects of xiao-qing-long-tang (XQLT) on bronchoconstriction and airway eosinophil infiltration in ovalbumin-sensitized guinea pigs: in vivo and in vitro studies. Allergy 2001, 56(12):1164-1171.
• [23]Kao ST, Yeh TJ, Hsieh CC, Shiau HB, Yeh FT, Lin JG: The effects of Ma-Xing-Gan-Shi-Tang on respiratory resistance and airway leukocyte infiltration in asthmatic guinea pigs. Immunopharmacol Immunotoxicol 2001, 23(3):445-458.
• [24]Kao ST, Yeh TJ, Hsieh CC, Yeh FT, Lin JG: Effect of San-Ao-Tang on immediate and late airway response and leukocyte infiltration in asthmatic guinea pigs. Immunopharmacol Immunotoxicol 2000, 22(1):143-162.
• [25]Busse PJ, Schofield B, Birmingham N, Yang N, Wen MC, Zhang T, Srivastava K, Li XM: The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged mice. Allergy Asthma Immunol 2010, 104(3):236-246.
• [26]Li XM, Wang QF, Schofield B, Lin J, Huang SK, Wang Q: Modulation of antigen-induced anaphylaxis in mice by a traditional chinese medicine formula, Guo Min Kang. Am J Chin Med 2009, 37(1):113-125.
• [27]Fang SP, Tanaka T, Tago F, Okamoto T, Kojima S: Immunomodulatory effects of gyokuheifusan on INF-gamma/IL-4 (Th1/Th2) balance in ovalbumin (OVA)-induced asthma model mice. Biol Pharm Bull 2005, 28(5):829-833.
• [28]Chang HC, Gong CC, Chen JL, Mak OT: Inhibitory effects of inhaled complex traditional Chinese medicine on early and late asthmatic responses induced by ovalbumin in sensitized guinea pigs. BMC Complement Altern Med 2011, 11:80. BioMed Central Full Text
• [29]Pelikan Z, Pelikan-Filipek M: The late asthmatic response to allergen challenge–Part I. Ann Allergy 1986, 56(5):414-420.
• [30]Abraham WM, Bourdelais AJ, Sabater JR, Ahmed A, Lee TA, Serebriakov I, Baden DG: Airway responses to aerosolized brevetoxins in an animal model of asthma. Am J Respir Crit Care Med 2005, 171(1):26-34.
• [31]Moiseeva EP, Bradding P: Mast cells in lung inflammation. In Mast cell biology: Contemporary and emerging topics. Edited by Gilfillan AM, Metcalfe DD. New York: LLandes Bioscience and Springer; 2011:235-269.
• [32]Undem BJ, Graziano FM, Buckner CK: Studies on beta-adrenoceptors of purified mast cells from guinea-pig lung. Eur J Pharmacol 1985, 109(3):413-416.
• [33]Abraham WM, Burch RM, Farmer SG, Sielczak MW, Ahmed A, Cortes A: A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep. Am Rev Respir Dis 1991, 143(4 Pt 1):787-796.
• [34]Curzen N, Rafferty P, Holgate ST: Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 1987, 42(12):946-952.
• [35]Rafferty P, Beasley R, Holgate ST: The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma. Am Rev Respir Dis 1987, 136(2):369-373.
• [36]Urata Y, Yoshida S, Irie Y, Tanigawa T, Amayasu H, Nakabayashi M, Akahori K: Treatment of asthma patients with herbal medicine TJ-96: a randomized controlled trial. Resp Med 2002, 96(6):469-474.
• [37]Naito A, Satoh H, Sekizawa K: Asthma as well as anxiety improved by the Kampo extract Saiboku-to. Eur J Intern Med 2005, 16(8):621.
• [38]Chan CK, Kuo ML, Shen JJ, See LC, Chang HH, Huang JL: Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial. Pediatr Asthma Allergy Immunol 2006, 17(5):316-322.
• [39]Li GZ, Chai OH, Lee MS, Han EH, Kim HT, Song CH: Inhibitory effects of Houttuynia cordata water extracts on anaphylactic reaction and mast cell activation. Biol Pharm Bull 2005, 28(10):1864-1868.
• [40]Drew CD, Knight GT, Hughes DT, Bush M: Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. Br J Clin Pharmacol 1978, 6(3):221-225.
• [41]Shibata H, Minami E, Hirata R, Mizutani N, Nabe T, Kohno S: Immediate inhibition by oral l-ephedrine of passive cutaneous anaphylaxis of rats: indirect inhibition of anaphylactic chemical mediator release from the mast cell. Inflamm Res 2000, 49(10):553-559.
• [42]Hashimoto K, Yanagisawa T, Okui Y, Ikeya Y, Maruno M, Fujita T: Studies on anti-allergic components in the roots of Asiasarum sieboldi. Planta Med 1994, 60(2):124-127.
• [43]Kim SJ, Gao Zhang C, Taek Lim J: Mechanism of anti-nociceptive effects of Asarum sieboldii Miq. radix: potential role of bradykinin, histamine and opioid receptor-mediated pathways. J Ethnopharmacol 2003, 88(1):5-9.
• [44]Quang TH, Ngan NT, Minh CV, Kiem PV, Tai BH, Thao NP, Song SB, Kim YH: Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii. Bioorg Med Chem Lett 2012, 22(7):2527-2533.
• [45]Saita E, Kishimoto Y, Tani M, Iizuka M, Toyozaki M, Sugihara N, Kondo K: Antioxidant Activities of Perilla frutescens against Low-Density Lipoprotein Oxidation in Vitro and in Human Subjects. J Oleo Sci 2012, 61(3):113-120.
• [46]Careau E, Sirois J, Bissonnette EY: Characterization of lung hyperresponsiveness, inflammation, and alveolar macrophage mediator production in allergy resistant and susceptible rats. Am J Respir Cell Mol Biol 2002, 26(5):579-586.
• [47]Li Y, Martin LD, Minnicozzi M, Greenfeder S, Fine J, Pettersen CA, Chorley B, Adler KB: Enhanced expression of mucin genes in a guinea pig model of allergic asthma. Am J Respir Cell Mol Biol 2001, 25(5):644-651.